|
A Bittersweet Reminder In Neon
Lights
Monday 18 December 2006: A striking neon artwork depicting proteins
related to deadly diseases will mesmerize passers-by in the centre of
London, and act as a bittersweet reminder of the devastation of serious
medical conditions.
215 Euston Road is the home of the UK's largest independent medical charity,
the Wellcome Trust, and its front windows are a unique opportunity for
the public to learn more about the science and issues surrounding health
and wellbeing today. Approximately 5,000 people pass-by the Wellcome Trust
on a daily basis.
Proteins play a key part in how our bodies interact with disease. The
Structural Genomics Consortium, which the Wellcome Trust part funds, has
had a crucial role in identifying the structure of some important proteins
related to human disease, including cancer, HIV, obesity and malaria.
Understanding the structures offers potential targets for novel drugs
to treat these conditions.
London designers Graphic Thought Facility have constructed a colourful
and thought provoking display depicting a number of these proteins in
bright neon signs that will attract the attention of busy onlookers.
Clare Matterson, Director, Medicine, Society and History, The Wellcome
Trust, comments: "Graphic Thought Facility's display relates
to biomedical issues of global significance where Wellcome Trust-funded
research is making a difference. Clearly the new display marks the beginning
of an exciting period of development on Euston Road, as we prepare for
the launch of our first public venue Wellcome Collection, in the summer
of next year."
Paul Neale, Director, Graphic Thought Facility, said: "It
is the first time we have experimented with neon on this scale, and the
results are impressive. We have worked closely with the Wellcome Trust
to understand the nature of these proteins. It's difficult to comprehend
how something so beautiful can represent such serious conditions."
The new window display will be unveiled to the public on Monday 18 December
2006.
Graphic Thought Facility's design is the third commission for the Wellcome
Trust's Gibbs Building. The first was a series developed by Doshi Levien
for the opening of the building in August 2004, and the second was by
Glasgow designers Timorous Beasties, inspired by the Wellcome Trust's
work on the human genome and malaria.
END
Notes To Editors
Media enquiries
Mike Findlay, Wellcome Trust
E m.findlay@wellcome.ac.uk
T +44 (0)20 7611 8612
The Wellcome Trust (www.wellcome.ac.uk)
The Wellcome Trust is the largest independent medical research charity in
the UK and the second largest in the world. It funds innovative biomedical
research, in the UK and internationally, spending around £500 million
each year to support the brightest scientists with the best ideas. The Wellcome
Trust is committed to public debate about biomedical research and its impact
on health and wellbeing.
Graphic Thought Facility (http://www.graphicthoughtfacility.com/)
Graphic Thought Facility is a London-based graphic design consultancy.
Established as a partnership in 1990 and as a limited company in 1997,
Graphic Thought Facility work on national and international projects.
Significant projects include brand-identity and signage for Frieze Art
Fair (2002-6); brand-identity for the Design Museum (2002) and exhibition
design their Designer of the Year (2002-6); re-branding, packaging, marketing
and press material for Habitat (1996-2002); store graphics and signage
for Marks & Spencer (2004-6); catalogue designs for the Saatchi Collection
(2002) and The Carnegie Museum of Arts' 54th International (2004).
The Structural Genomics Consortium (SGC) http://www.sgc.utoronto.ca/
SGC is a not-for-profit organization that aims to determine the three
dimensional structures of proteins of medical relevance, and place them
in the public domain without restriction. The SGC operates out of the
Universities of Oxford and Toronto and Karolinska Institutet, Stockholm.
The SGC works on structures of proteins from its Target List of ~2,000
proteins, which comprises human proteins associated with diseases such
as cancer, diabetes, inflammation, and genetic diseases, as well as proteins
from human parasites such as those that cause malaria.
Wellcome Collection (www.wellcomecollection.org.uk)
The Wellcome Trust's former headquarters, The Wellcome Building on London's
Euston Road, has been redesigned by Hopkins Architects to become a new
£30m public venue opening in summer 2007. Free to all, Wellcome
Collection will explore the connections between medicine, life and art
in the past, present and future. The building will comprise three galleries,
a public events space, the Wellcome Library, a café, a bookshop,
conference facilities and a members' club.
The five neon signs are based on the following protein structures:
Leptin and Obesity
Protein Database number 1AX8
Leptin is the protein that regulates how people's bodies store fat. It
inhibits eating, by making you feel full instead of hungry. It also makes
you burn off calories. Leptin was originally discovered by studying mutant
mice that didn't know when to stop eating and so became huge. In 1994
researchers discovered that the reason these mice ate so much was that
they couldn't produce proper leptin.
In rare cases, people can't make leptin properly and become obese. Leptin
treatment can help them lose weight. For most of the population however
there appears to be no correlation between obesity and the different forms
of the gene that produces leptin.
Developing Antibiotics
Plasmodium yoelii holo-(Acyl-carrier protein) synthase
SGC Database number 2BDD
Fatty acids are used by all organisms. They make up the membranes that
hold cells and their contents together and store energy. This protein
is part of the pathway used to make fatty acids by Plasmodium yoelii,
one of the protozoans that cause malaria in mice. Bacteria use a very
similar protein so that they can grow and divide to produce new bacteria.
Humans use a different pathway which doesn't include a protein like this
to make fatty acids. By designing drugs to target such proteins, which
bacteria and malaria parasites use and humans don't, it could be possible
to develop antimalarial treatments and/or antibiotics that kill bacteria
without harming their human hosts.
Fighting Cancer
Human WD repeat domain protein 5 (WDR5)
SGC Database number 2GNQ
WDR5 is one of the huge number of proteins in any cell whose job it is
to switch genes on and off at the right times. The DNA in which our genes
are encoded is wrapped around proteins called histones, and whenever a
cell wants to turn on a gene it has to first unwrap them. WDR5 is one
of the proteins that aid this unwrapping. In cancer, cells divide because
the wrong genes are switched on or off. Since many of the genes that WDR5
helps to control are involved in shaping an animal as it grows, turning
them on in an adult can mean new disorganised growth which can form a
tumour.
Researching Drugs to Treat Malaria
PPWD1 from the malaria parasite Plasmodium falciparum
SGC Database number 2FU0
PPWD1 is a protein that helps other proteins fold into the correct shape
as they are made. The human version is involved in cell division and is
part of the immune system. Some drugs that are used to shut down the immune
system - following transplant surgery, for example, or in patients with
inflammation - act by forming a complex with PPWD1. This PPWD1 is taken
from one of the protozoans that causes malaria in humans, called Plasmodium
falciparum. Because this protein is so similar to the human version, drugs
originally designed for use in humans target this protein in the Plasmodium
and stop it working, thus potentially preventing the development of malaria.
Studying HIV
SGC Database number 2C46
Like any virus, HIV (which causes AIDS) takes over the machinery of a
host cell in order to reproduce. One of the human proteins that it hijacks
is Human Capping Enzyme 1. Normally this protein is involved in the process
of using the instructions in human DNA to build other proteins. These
instructions are copied into a portable form, called messenger RNA, and
Human Capping Enzyme 1 modifies the messenger RNA, adding a chemical 'cap'.
The cap signals to the cell that it needs to make a protein based on this
RNA. HIV uses Human Capping Enzyme 1 to attach cap signals to its own
RNA, tricking the human cell into making HIV proteins and helping the
virus reproduce.
END TO ALL
|